Moreover, there are cases of clinically-evident AAS which could not be attributed to mutations in FGD1. As a matter of fact, some researchers argue that the majority of AAS cases are still to be characterized molecularly, with FGD1 mutations being established in a mere 20% of the cases [6]. This evidence concerns the gene FGD1 and Aarskog-Scott syndrome, X-linked.